CYTEK BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
CYTEK BIOSCIENCES, INC. (CTKB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.43 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-05
- CYTEK BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 102.88K shares, a 23.39% decline year-over-year.
- CYTEK BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.32M shares, a 44.91% decline year-over-year.
- CYTEK BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 10.00K shares.
- CYTEK BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 10.00K shares.
- CYTEK BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.56M shares, a 33.50% increase from fiscal 2024.
- CYTEK BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.92M shares, a 47.90% increase from fiscal 2023.
- CYTEK BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.30M shares, a 81.16% increase from fiscal 2022.
- CYTEK BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 715.35K shares, a 83.53% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 102.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 1.43M shares 10-Q · filed 2026-08-05 | 1.44M shares derived: sum of 3 quarters · filed 2026-08-05 | 1.45M shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 1.32M shares 10-Q · filed 2026-05-07 | 1.33M shares derived: sum of 2 quarters · filed 2026-05-07 | 1.34M shares derived: sum of 3 quarters · filed 2026-05-07 | 1.48M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 10.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 20.00K shares derived: sum of 2 quarters · filed 2026-02-26 | 154.30K shares derived: sum of 3 quarters · filed 2026-02-26 | 2.56M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 10.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 144.30K shares derived: sum of 2 quarters · filed 2025-11-05 | 2.55M shares 10-Q · filed 2025-11-05 | 2.55M shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | 134.30K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 2.54M shares 10-Q · filed 2025-08-06 | 2.54M shares derived: sum of 3 quarters · filed 2026-02-26 | 2.54M shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | 2.40M shares 10-Q · filed 2025-05-08 | 2.40M shares derived: sum of 2 quarters · filed 2026-02-26 | 2.40M shares derived: sum of 3 quarters · filed 2026-02-26 | 2.79M shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 0.00 shares derived: sum of 2 quarters · filed 2026-02-26 | 388.36K shares derived: sum of 3 quarters · filed 2026-02-26 | 1.92M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 0.00 shares 10-Q · filed 2025-11-05 | 388.36K shares derived: sum of 2 quarters · filed 2025-11-05 | 1.92M shares 10-Q · filed 2024-11-07 | 1.92M shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | 388.36K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 1.92M shares 10-Q · filed 2024-08-06 | 1.92M shares derived: sum of 3 quarters · filed 2025-02-28 | 1.98M shares derived: sum of 4 quarters · filed 2025-02-28 |
| 2024-03-31 | 1.53M shares 10-Q · filed 2024-05-08 | 1.53M shares derived: sum of 2 quarters · filed 2025-02-28 | 1.59M shares derived: sum of 3 quarters · filed 2025-02-28 | 1.74M shares derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | 61.00K shares derived: sum of 2 quarters · filed 2025-02-28 | 212.21K shares derived: sum of 3 quarters · filed 2025-02-28 | 1.30M shares 10-K · filed 2025-02-28 |
| 2023-09-30 | 61.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 212.21K shares derived: sum of 2 quarters · filed 2023-11-14 | 1.30M shares 10-Q · filed 2023-11-14 | 1.32M shares derived: sum of 4 quarters · filed 2024-03-13 |
| 2023-06-30 | 151.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 1.23M shares 10-Q · filed 2023-08-08 | 1.26M shares derived: sum of 3 quarters · filed 2024-03-13 | 1.26M shares derived: sum of 4 quarters · filed 2024-03-13 |
| 2023-03-31 | 1.08M shares 10-Q · filed 2023-05-09 | 1.11M shares derived: sum of 2 quarters · filed 2024-03-13 | 1.11M shares derived: sum of 3 quarters · filed 2024-03-13 | 1.34M shares derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-12-31 | 24.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 24.60K shares derived: sum of 2 quarters · filed 2024-03-13 | 256.99K shares derived: sum of 3 quarters · filed 2024-03-13 | 715.35K shares 10-K · filed 2024-03-13 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 232.39K shares derived: sum of 2 quarters · filed 2022-11-09 | 690.75K shares 10-Q · filed 2022-11-09 | 719.35K shares derived: sum of 4 quarters · filed 2023-03-01 |
| 2022-06-30 | 232.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | 690.75K shares 10-Q · filed 2022-08-10 | 719.35K shares derived: sum of 3 quarters · filed 2023-03-01 | 3.58M shares derived: sum of 4 quarters · filed 2023-03-01 |
| 2022-03-31 | 458.36K shares 10-Q · filed 2022-05-12 | 486.96K shares derived: sum of 2 quarters · filed 2023-03-01 | 3.34M shares derived: sum of 3 quarters · filed 2023-03-01 | |
| 2021-12-31 | 28.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | 2.89M shares derived: sum of 2 quarters · filed 2023-03-01 | 4.34M shares 10-K · filed 2023-03-01 | |
| 2021-09-30 | 2.86M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 4.32M shares 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | 1.46M shares 10-Q · filed 2021-09-03 | |||
| 2020-12-31 | 1.75M shares 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |